Low expression of SREBP1 reduces the deacetylated inhibition of E-cadherin, attenuates the effect of the Snail/HDAC1/2 inhibitory complex, and blocks breast cancer cell growth and metastasis [97]. Here, SREBF1 is linked to breast cancer.